For the first time in over 30 years, the US FDA has approved a new antidepressant called Spravato™ (esketamine) for treatment-resistant depression in adults.
A recent study has indicated that vitamin D affects perineuronal nets within the brain, which could facilitate the loss of brain plasticity.
Cannabis use amongst adolescents has been associated with increased risk of depression and anxiety in adulthood, according to a new study.
In the largest study of its kind, researchers have identified hundreds of genes newly linked to depression, shedding light on the origins of the condition.
Two clinical trials of a combined therapy targeting the opioid system have suggested significant symptom reduction in people with major depression.
A preliminary study has revealed that athletes with ADHD may be at greater risk for experiencing persistent anxiety and depression after a concussion.
Scientists have demonstrated how variations in a gene linked to anxiety and depression could affect a patient’s response to treatment.
On-going research reveals that deep brain stimulation may help individuals with chronic depression and could help them regain their lives.
Over a third of adults in the USA may be unknowingly using prescription medications that could increase the risk of depression and suicide.
ALKS 5461 accepted for review following previous refusal-to-file for depression: industry news round-up
In this week’s industry news round-up, we’ve chosen the latest updates from a wide range of disorders extending from depression to multiple sclerosis.